TS
TVRD

Thomas Steyer’s Tvardi Therapeutics TVRD Stock Holding History

Thomas Steyer’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,438
Closed -$68.2K – 192
2026
Q1 		$68.2K Sell
21,438
-21,787
-50% -$85.4K ﹤0.01% 165
2025
Q4 		$186K Hold
43,225
– – ﹤0.01% 139
2025
Q3 		$1.68M Hold
43,225
– – 0.01% 82
2025
Q2 		$1.01M Sell
43,225
-3
-0% -$71 ﹤0.01% 90
2025
Q1 		$658K Hold
43,228
– – ﹤0.01% 94
2024
Q4 		$794K Sell
43,228
-1
-0% -$11 ﹤0.01% 100
2024
Q3 		$479K Hold
43,229
– – ﹤0.01% 109
2024
Q2 		$402K Hold
43,229
– – ﹤0.01% 113
2024
Q1 		$1.42M Hold
43,229
– – 0.01% 117
2023
Q4 		$1.16M Sell
43,229
-3,065
-7% -$127K 0.01% 104
2023
Q3 		$2.8M Hold
46,294
– – 0.01% 105
2023
Q2 		$4.72M Sell
46,294
-9,133
-16% -$1.26M 0.02% 105
2023
Q1 		$9.8M Sell
55,427
-2,190
-4% -$733K 0.05% 102
2022
Q4 		$22.3M Sell
57,617
-11,827
-17% -$4.49M 0.13% 80
2022
Q3 		$23.4M Hold
69,444
– – 0.13% 96
2022
Q2 		$22.8M Hold
69,444
– – 0.12% 95
2022
Q1 		$30.4M Buy
69,444
+13,888
+25% +$5.7M 0.15% 82
2021
Q4 		$24.4M Hold
55,556
– – 0.12% 85
2021
Q3 		$30.9M Hold
55,556
– – 0.14% 86
2021
Q2 		$28.5M Sell
55,556
-12,916
-19% -$8.18M 0.12% 89
2021
Q1 		$53.5M Hold
68,472
– – 0.27% 70
2020
Q4 		$37.3M Buy
68,472
+5,972
+10% +$3.13M 0.22% 73
2020
Q3 		$28.6M Sell
62,500
-1,389
-2% -$807K 0.2% 78
2020
Q2 		$39.3M Hold
63,889
– – 0.31% 64
2020
Q1 		$30.4M Hold
63,889
– – 0.26% 56
2019
Q4 		$37.1M Buy
63,889
+4,167
+7% +$2.92M 0.25% 64
2019
Q3 		$39.3M Buy
59,722
+33,296
+126% +$27.7M 0.3% 51
2019
Q2 		$20.5M Buy
+26,426
New +$18.6M 0.13% 77

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Thomas Steyer's TVRD Position: Q2 2026 in Review

Thomas Steyer sold out of Tvardi Therapeutics (TVRD) in Q2 2026, closing a stake of 21,438 shares — an estimated $68.2K sold.

Thomas Steyer first reported a position in TVRD in Q2 2019 and held it in 28 quarters. The position peaked at $53.5M in Q1 2021. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Thomas Steyer reported no remaining Tvardi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 21,438 Tvardi Therapeutics shares in Q2 2026, an estimated $68.2K.
  • Thomas Steyer first reported a position in Tvardi Therapeutics in Q2 2019 and held it in 28 quarters.
  • Thomas Steyer's Tvardi Therapeutics position peaked at $53.5M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.